Pharma channel feed

There’s a new team oc­cu­py­ing the ex­ec­u­tive suite at Mer­ck. And they’ve got a new game plan

4 years ago
Bioregnum

HHS cracks down on As­traZeneca, Eli Lil­ly, No­var­tis, No­vo Nordisk and Sanofi for lim­it­ing ac­cess to dis­count­ed drugs un­der the 340B pro­gram

4 years ago
FDA+

House com­mit­tee un­cov­ers how Hu­mi­ra’s price spiked by 470% as Ab­b­Vie ex­ecs cashed bonus­es tied to the hikes

4 years ago
FDA+

SCO­TUS de­clines to re­view En­brel biosim­i­lar case, tee­ing up 30+ years of ex­clu­siv­i­ty and $20B more for Am­gen’s block­buster

4 years ago
FDA+

#ACC21: No­var­tis' En­tresto takes its 2nd fail­ure of the week­end at ACC, show­ing no ben­e­fit in most dire heart fail­ure pa­tients

4 years ago
R&D

#ACC21: As­traZeneca's Farx­i­ga missed big on Covid-19 study, but it's tak­ing SGLT2 safe­ty da­ta as a sil­ver lin­ing

4 years ago
R&D

#ACC21: Re­gen­eron's Evkeeza shows promise in curb­ing high triglyc­erides, but will ge­net­ic dis­par­i­ties lim­it use?

4 years ago
R&D

#ACC21: Pfiz­er, Bris­tol My­er­s' Eliquis flops in post-heart surgery pa­tients, spurring an 'un­ex­plained sig­nal' in cer­tain deaths

4 years ago
R&D

#ACC21: No­var­tis whiffs on En­tresto study af­ter heart at­tacks — but that does­n't mean it's go­ing down qui­et­ly

4 years ago

In­cyte’s PD-(L)1 in­hibitor head­ed for an ODAC show­down next month

5 years ago
FDA+

Third time’s the charm as Heron wins FDA nod for non-opi­oid anes­thet­ic Zyn­relef

5 years ago
FDA+

Pfiz­er calls pro­posed IP waiv­er for Covid vac­cines a 'dis­trac­tion' from find­ing re­al so­lu­tions on ac­cess

5 years ago
Coronavirus

FDA un­veils six ICH guide­lines ahead of meet­ing with Health Cana­da

5 years ago
FDA+

Sanofi, Glax­o­SmithK­line, Boehringer ac­cused of play­ing games, de­stroy­ing emails re­lat­ed to law­suit over con­t­a­m­i­nat­ed Zan­tac

5 years ago

Alvotech takes Ab­b­Vie to court over al­leged patent 'mine­field' sur­round­ing megablock­buster Hu­mi­ra

5 years ago

Is re­mote work here to stay for bio­phar­ma? Ear­ly in­di­ca­tions point to yes

5 years ago

Ab­b­Vie makes a hefty play to boost aes­thet­ics busi­ness, pay­ing $550M for non-in­va­sive body sculpt­ing de­vice

5 years ago
Deals

Covid-19 roundup: Pfiz­er sub­mits vac­cine for full ap­proval; Merkel op­pos­es Biden pro­pos­al to sus­pend IP for vac­cines

5 years ago
Coronavirus

As­traZeneca caps PD-L1/CT­LA-4/chemo com­bo come­back with OS win. Is treme­li­mum­ab fi­nal­ly ready for ap­proval?

5 years ago
R&D

Ad­comm splits slight­ly in fa­vor of FDA ap­prov­ing Chemo­Cen­tryx’s rare dis­ease drug

5 years ago
FDA+

Drug pric­ing watch­dog joins the cho­rus of crit­ics on Bio­gen's ad­u­canum­ab: What about charg­ing $2,560 per year?

5 years ago

Biden ad­min­is­tra­tion backs a po­lar­iz­ing pro­pos­al to waive IP for all Covid-19 vac­cines

5 years ago
FDA+
Manufacturing

FDA ex­tends re­search agree­ment with MIT-li­censed or­gan-on-chip sys­tems

5 years ago
FDA+

In quest to meet user fee goals, FDA’s per­for­mance con­tin­ues down­ward trend

5 years ago
FDA+
First page Previous page 240241242243244245246 Next page Last page
A service from the Financial Times